Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Université Laval

$120,000.00

P2Y6 antagonists as a potential therapy for inflammatory bowel disease

FY 2025-26

Summary
Ulcerative colitis (UC) and Crohn's disease (CD) are the two main forms of inflammatory bowel disease (IBD), a chronic condition of the intestines that affects about 0.8% of Canadians (roughly 1 in 125 people). IBD causes persistent inflammation in the gut, leading to symptoms such as abdominal pain, diarrhea, fatigue, and poor sleep. These symptoms can make everyday activities challenging, often resulting in missed work or school, social limitations, and increased stress or mental health concerns. Current treatments provide relief for some patients, but many continue to experience flare-ups and long-term complications, highlighting the urgent need for new and more effective therapies. Our previous research has shown that a receptor called P2Y6 plays a key role in driving intestinal inflammation. In my PhD project, I will evaluate five new P2Y6 blockers that have been designed for use in humans. If successful, these compounds could reduce inflammation and improve symptoms in patients with IBD. In addition, we will investigate the underlying mechanisms of this proinflammatory receptor. This research will provide a deeper understanding of how IBD develops and progresses. More importantly, it has the potential to guide the development of new treatments that alleviate pain, fatigue, and other symptoms for people living with IBD, ultimately improving their quality of life. By targeting P2Y6, a molecule we have recently identified as a driver of intestinal inflammation, this work may open the door to safer and more effective therapies for patients who currently have limited treatment options.
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
559437
Name
guedes manzoni alessandra
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
P2Y6 antagonists as a potential therapy for inflammatory bowel disease
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Antagonists; Crohn'S Disease; Inflammation; Inflammatory Bowel Disease; P2 Receptor; Ulcerative Colitis
Abstract
Ulcerative colitis (UC) and Crohn's disease (CD) are the two main forms of inflammatory bowel disease (IBD), a chronic condition of the intestines that affects about 0.8% of Canadians (roughly 1 in 125 people). IBD causes persistent inflammation in the gut, leading to symptoms such as abdominal pain, diarrhea, fatigue, and poor sleep. These symptoms can make everyday activities challenging, often resulting in missed work or school, social limitations, and increased stress or mental health concerns. Current treatments provide relief for some patients, but many continue to experience flare-ups and long-term complications, highlighting the urgent need for new and more effective therapies. Our previous research has shown that a receptor called P2Y6 plays a key role in driving intestinal inflammation. In my PhD project, I will evaluate five new P2Y6 blockers that have been designed for use in humans. If successful, these compounds could reduce inflammation and improve symptoms in patients with IBD. In addition, we will investigate the underlying mechanisms of this proinflammatory receptor. This research will provide a deeper understanding of how IBD develops and progresses. More importantly, it has the potential to guide the development of new treatments that alleviate pain, fatigue, and other symptoms for people living with IBD, ultimately improving their quality of life. By targeting P2Y6, a molecule we have recently identified as a driver of intestinal inflammation, this work may open the door to safer and more effective therapies for patients who currently have limited treatment options.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
guedes manzoni, alessandra
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~